Clinical Trials in Shenzhen, Nanshan
2 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled721 locationsNCT05712200
Recruiting
Phase 3
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)
Head and Neck Squamous Cell Carcinomas
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University537 enrolled3 locationsNCT05582265